Researchers are exploring a novel quintuple agonist that targets five pathways, including GLP-1R, GIPR, and three PPARs. This innovative approach combines the benefits of incretin and PPAR pathways, ...
Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback